. Author manuscript; available in PMC: 2014 Nov 1.

Published in final edited form as: Br J Haematol. 2013 Sep 6;163(3):10.1111/bjh.12542. doi: 10.1111/bjh.12542

Table I.

COP-R Schema used in this study

Day	−3	−2	−1	0	1	2	3	4	5	6
Vincristine (1 mg/m²)				•
Prednis(ol)one (60 mg/m²/day)				• •	• •	• •	• •	• •	• •	• •
Cyclophosphamide (300 mg/m²)				•
Rasburicase^**(0.2 mg/m²)	• ^**	• ^**	• ^**	•	^***	^***	^***	^***	^***
IT MTX/HC				•

^**

Prereduction (days −3, −2, −1): Patients with Hyperuricaemia (serum uric acid ≥475.8 μmol/l) and clinical suspicion of advanced B-cell NHL and/or B-ALL

^***

A minimum of 1 dose rasburicase on Day 0(0°) and every 24 h for up to a maximum of 5 doses.

IT MTX/HC: intrathecal methotrexate and hydrocortisone